- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arena Pharmaceuticals Inc (ARNA)
NASDAQ
Symbol | Exchange | Currency |
|---|
65.30
+0.77(+1.19%)
- Volume:197,450
- Bid/Ask:63.00/66.70
- Day's Range:63.78 - 65.79
ARNA Overview
- Prev. Close
- 64.53
- Day's Range
- 63.78-65.79
- Revenue
- 60K
- Open
- 64.58
- 52 wk Range
- 59.55-90.19
- EPS
- -7.37
- Volume
- 197,450
- Market Cap
- 3.96B
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 562,486
- P/E Ratio
- -
- Beta
- 0.54
- 1-Year Change
- 4.7%
- Shares Outstanding
- 60,696,200
- Next Earnings Date
- Nov 10, 2021
What is your sentiment on Arena Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.
Arena Pharmaceuticals Inc News
- JonesTrading Stick to Their Buy Rating for Arena Pharmaceuticals
- ByInvesting.com-
JonesTrading analyst Prakhar Agrawal maintained a Buy rating on Arena Pharmaceuticals on Wednesday, setting a price target of $94, which is approximately 34.88% above the present...
- Arena Pharma's etrasimod an Orphan drug in U.S. for eosinophilic esophagitis
- BySeeking Alpha-
The FDA has granted Orphan Drug Designation status to Arena Pharmaceuticals' (ARNA) etrasimod, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the...
Arena Pharmaceuticals Inc Analysis
- 2 Recently Beaten Down ETFs That Could Rebound In May
Broader markets are close to record highs. Year-to-date, the Dow Jones Industrial Average, the S&P 500 and the NASDAQ 100 are up around 11.5%, 11.6% and 8.2%,...
- A Few Top Charts
Apache Corporation (NYSE:APA) in the oil sector is still hanging in there. On Thursday, it popped 33 cents, or 2.38%, to 14.22,...
- 6 Stocks To Watch: Arena Pharma, Baozun, NIO, Precigen, Sea Limited, Stratasys
1. Arena PharmaceuticalsArena Pharmaceuticals (NASDAQ:ARNA) broke out, and I put a swing on it on Tuesday. I like the look when it broke through resistance, and then it kept...
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Neutral | Buy | Sell | Buy |
| Technical Indicators | Strong Sell | Neutral | Strong Buy | Strong Sell | Buy |
| Summary | Sell | Neutral | Strong Buy | Strong Sell | Buy |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,660.30 | 2,668.00 | 2,596.00 | +91.9 | +3.58% | 2.08M | NASDAQ | |||
| 369.79 | 375.33 | 357.19 | +18.60 | +5.30% | 33.69M | NASDAQ | |||
| 6.66 | 7.01 | 6.66 | -0.300 | -4.31% | 36.22K | NASDAQ | |||
| 195.58 | 197.00 | 192.50 | -0.36 | -0.18% | 19.57M | NASDAQ | |||
| 38.69 | 38.96 | 38.42 | +0.14 | +0.36% | 112.79K | NYSE | |||
| 6.94 | 7.28 | 6.76 | -0.300 | -4.14% | 11.79M | NYSE | |||
| 206.53 | 206.89 | 203.56 | -7.51 | -3.51% | 25.54M | NYSE | |||
| 2,756.30 | 2,776.20 | 2,694.00 | +89.8 | +3.37% | 1.32M | NASDAQ | |||
| 8.05 | 8.44 | 7.97 | -0.57 | -6.61% | 28.13M | NASDAQ | |||
| 20.01 | 20.65 | 19.75 | -0.50 | -2.44% | 728.03K | NASDAQ | |||
| 0.0029 | 0.00 | 0.00 | 0.0000 | 0.00% | 135.52M | OTC Markets | |||
| 28.15 | 28.21 | 27.93 | +0.14 | +0.50% | 30.23M | NYSE | |||
| 4.64 | 4.857 | 4.415 | +0.040 | +0.87% | 49.72K | NASDAQ | |||
| 86.22 | 86.26 | 84.74 | +1.41 | +1.66% | 834.46K | NYSE | |||
| 106.48 | 106.50 | 106.43 | 0.00 | 0.00% | 0.00 | NASDAQ |
Arena Pharmaceuticals Inc Company Profile
Arena Pharmaceuticals Inc Company Profile
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn’s disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.
Read More
- 2021-06-17 12:22:37
long hold - 2021-03-03 00:36:04Better wear a cup and a helmet at breakfast.
- 2020-10-22 17:18:13
2021 will be a huuugggeee year for ARNA.- 2020-10-27 13:35:34
good to hear but why thx - 2020-11-24 17:15:49
Why is that?
- 2020-07-08 20:39:24Good breakout from pennant
- 2017-06-12 17:54:03Long term BUY. Several positive catalysts occurring in 2017.
- 2016-02-19 16:58:37Option BUY.
- 2017-02-18 18:26:35Hope you right .
- 2018-03-20 16:00:16How many shares,per purchases
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.